These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31968251)

  • 1. Inhibition of EZH2 Catalytic Activity Selectively Targets a Metastatic Subpopulation in Triple-Negative Breast Cancer.
    Yomtoubian S; Lee SB; Verma A; Izzo F; Markowitz G; Choi H; Cerchietti L; Vahdat L; Brown KA; Andreopoulou E; Elemento O; Chang J; Inghirami G; Gao D; Ryu S; Mittal V
    Cell Rep; 2020 Jan; 30(3):755-770.e6. PubMed ID: 31968251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpression of CDCA7 predicts poor prognosis and induces EZH2-mediated progression of triple-negative breast cancer.
    Ye L; Li F; Song Y; Yu D; Xiong Z; Li Y; Shi T; Yuan Z; Lin C; Wu X; Ren L; Li X; Song L
    Int J Cancer; 2018 Nov; 143(10):2602-2613. PubMed ID: 30151890
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor-Intrinsic Enhancer of Zeste Homolog 2 Controls Immune Cell Infiltration, Tumor Growth, and Lung Metastasis in a Triple-Negative Breast Cancer Model.
    Monterroza L; Parrilla MM; Samaranayake SG; Rivera-Rodriguez DE; Yoon SB; Bommireddy R; Hosten J; Barragan LC; Marcus A; Dobosh BS; Selvaraj P; Tirouvanziam R
    Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic Co-Deregulation of EZH2/TET1 is a Senescence-Countering, Actionable Vulnerability in Triple-Negative Breast Cancer.
    Yu Y; Qi J; Xiong J; Jiang L; Cui D; He J; Chen P; Li L; Wu C; Ma T; Shao S; Wang J; Yu D; Zhou B; Huang D; Schmitt CA; Tao R
    Theranostics; 2019; 9(3):761-777. PubMed ID: 30809307
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CDK2-mediated site-specific phosphorylation of EZH2 drives and maintains triple-negative breast cancer.
    Nie L; Wei Y; Zhang F; Hsu YH; Chan LC; Xia W; Ke B; Zhu C; Deng R; Tang J; Yao J; Chu YY; Zhao X; Han Y; Hou J; Huo L; Ko HW; Lin WC; Yamaguchi H; Hsu JM; Yang Y; Pan DN; Hsu JL; Kleer CG; Davidson NE; Hortobagyi GN; Hung MC
    Nat Commun; 2019 Nov; 10(1):5114. PubMed ID: 31704972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EZH2 mutation is associated with the development of visceral metastasis by enhancing proliferation and invasion and inhibiting apoptosis in breast cancer cells.
    Wu F; Li N; Wu X; Chen M; Huang W; Chen X; Hong Y; Wang L; Chen K; Lin L; You M; Liu J
    BMC Cancer; 2024 Sep; 24(1):1166. PubMed ID: 39300407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Curcumin inhibits the growth of triple-negative breast cancer cells by silencing EZH2 and restoring DLC1 expression.
    Zhou X; Jiao D; Dou M; Zhang W; Lv L; Chen J; Li L; Wang L; Han X
    J Cell Mol Med; 2020 Sep; 24(18):10648-10662. PubMed ID: 32725802
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EZH2-H3K27me3 mediated KRT14 upregulation promotes TNBC peritoneal metastasis.
    Verma A; Singh A; Singh MP; Nengroo MA; Saini KK; Satrusal SR; Khan MA; Chaturvedi P; Sinha A; Meena S; Singh AK; Datta D
    Nat Commun; 2022 Nov; 13(1):7344. PubMed ID: 36446780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The WNT10B Network Is Associated with Survival and Metastases in Chemoresistant Triple-Negative Breast Cancer.
    El Ayachi I; Fatima I; Wend P; Alva-Ornelas JA; Runke S; Kuenzinger WL; Silva J; Silva W; Gray JK; Lehr S; Barch HC; Krutilina RI; White AC; Cardiff R; Yee LD; Yang L; O'Regan RM; Lowry WE; Seagroves TN; Seewaldt V; Krum SA; Miranda-Carboni GA
    Cancer Res; 2019 Mar; 79(5):982-993. PubMed ID: 30563890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CCN6 Suppresses Metaplastic Breast Carcinoma by Antagonizing Wnt/β-Catenin Signaling to Inhibit EZH2-Driven EMT.
    Gonzalez ME; Brophy B; Eido A; Leonetti AE; Djomehri SI; Augimeri G; Carruthers NJ; Cavalcante RG; Giordano F; Andò S; Nesvizhskii AI; Fearon ER; Kleer CG
    Cancer Res; 2024 Oct; 84(19):3235-3249. PubMed ID: 39024552
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
    Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
    Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Metabolic-Epigenetic Mechanism Directs Cell Fate and Therapeutic Sensitivity in Breast Cancer.
    Bernard MJ; Goldstein AS
    Cancer Res; 2024 May; 84(9):1382-1383. PubMed ID: 38330100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of Poliovirus Receptor-like 3 Protein as a Prognostic Factor in Triple-Negative Breast Cancer.
    Leone GM; Mangano K; Caponnetto S; Fagone P; Nicoletti F
    Cells; 2024 Aug; 13(15):. PubMed ID: 39120328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Interaction of EZH2 and P65 is involved in the arsenic trioxide-induced anti-angiogenesis in human triple-negative breast cancer cells.
    Jiang F; Li Y; Si L; Zhang Z; Li Z
    Cell Biol Toxicol; 2019 Aug; 35(4):361-371. PubMed ID: 30612216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EZH2- H3K27me3-DNMT1 complex orchestrates epigenetic silencing of the wwc1 gene, a Hippo/YAP pathway upstream effector, in breast cancer epithelial cells.
    Liu X; Li C; Zhang R; Xiao W; Niu X; Ye X; Li Z; Guo Y; Tan J; Li Y
    Cell Signal; 2018 Nov; 51():243-256. PubMed ID: 30121333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EZH2 induces the expression of miR-1301 as a negative feedback control mechanism in triple negative breast cancer.
    Wu Q; Chen Z; Zhang G; Zhou W; Peng Y; Liu R; Chen C; Feng J
    Acta Biochim Biophys Sin (Shanghai); 2018 Jul; 50(7):693-700. PubMed ID: 29790898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast Cancer.
    Deblois G; Tonekaboni SAM; Grillo G; Martinez C; Kao YI; Tai F; Ettayebi I; Fortier AM; Savage P; Fedor AN; Liu X; Guilhamon P; Lima-Fernandes E; Murison A; Kuasne H; Ba-Alawi W; Cescon DW; Arrowsmith CH; De Carvalho DD; Haibe-Kains B; Locasale JW; Park M; Lupien M
    Cancer Discov; 2020 Sep; 10(9):1312-1329. PubMed ID: 32546577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ZRANB1 Is an EZH2 Deubiquitinase and a Potential Therapeutic Target in Breast Cancer.
    Zhang P; Xiao Z; Wang S; Zhang M; Wei Y; Hang Q; Kim J; Yao F; Rodriguez-Aguayo C; Ton BN; Lee M; Wang Y; Zhou Z; Zeng L; Hu X; Lawhon SE; Siverly AN; Su X; Li J; Xie X; Cheng X; Liu LC; Chang HW; Chiang SF; Lopez-Berestein G; Sood AK; Chen J; You MJ; Sun SC; Liang H; Huang Y; Yang X; Sun D; Sun Y; Hung MC; Ma L
    Cell Rep; 2018 Apr; 23(3):823-837. PubMed ID: 29669287
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-binding protein MSI2 isoforms expression and regulation in progression of triple-negative breast cancer.
    Li M; Li AQ; Zhou SL; Lv H; Wei P; Yang WT
    J Exp Clin Cancer Res; 2020 May; 39(1):92. PubMed ID: 32448269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.